Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 3, 2003, Pages 314-319

  Fernandez I ^a   Castellano, G ^a   De Salamanca, R E ^a   Colina, F ^a   Gomez De La Camara A ^a   Moran M J ^a   Munoz R ^a   Solís Herruzo, Jose A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Chronic hepatitis; HFE gene mutations; Iron status

Indexed keywords

ANTIVIRUS AGENT; GENOMIC DNA; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENE MUTATION; HEADACHE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS HEPATITIS; VIRUS LOAD;

EID: 0037361938     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310000672a     Document Type: Article

References (38)

1. Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest 1976;58:1089-97.
2. Meissner PN, Hift RJ, Kirsch RE. The porphyrias. In: Arias IM, Boyer JL, Chisari FV, Fausto N, Schachter D, Shafritz DA, editors. The liver. Biology and pathobiology, 4th edn. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2001:311-29.
3. Elder GH. Porphyria cutanea tarda. Semin Liv Dis 1998;18:67-75.
4. Bruguera M. Liver involvement in porphyria. Sere Dermatol 1986;5:178-85.
5. Cortes JM, Oliva H, Paradinas FJ, Hernández Guio C. The pathology of the liver in porphyria cutanea tarda. Histopathology 1980;4:471-85.
6. Lefkowitch JH, Grossman ME. Hepatic pathology in porphyria cutanea tarda. Liver 1983;3:19-29.
7. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-9.
8. DeCastro M, Sánchez J, Herrera JF, Cháves A, Durán R, García-Buey L, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17: 551-7.
9. Herrero C, Vicente A, Bruguera M, Ercilla MG, Barrera JM, Vidal J, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993;341:778-89.
10. Moran MJ, Fontanellas A, Brudieux E, Hombrados I, De Ledinghen V, Couzigou P, et al. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection. Hepatology 1998;27:584-9.
11. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
12. Sheikh MY, Wright RA, Burruss JB. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci 1998;43:529-33.
13. Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997;44:525-8.
14. Rich JD, Mylonakis E, Nossa R, Chapnick RM. Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C. Dig Dis Sci 1999;44:1034-7.
15. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-4.
16. Scheuer PJ, Lefkowitch JH. Disturbances of cooper and iron metabolism. In: Scheuer PJ, Lefkowitch JH, editors. Liver biopsy interpretation. BarCelona: W. B. Saunders; 2000:270-83.
17. Reichen J, Bianchi L, Buhler H, Dolivo N, Gonvers JJ, Lavanchy D, et al. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. Swiss Association for the Study of the Liver. J Hepatol 1996;25:275-82.
18. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26 Suppl 1:122S-7S.
19. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1326-9.
20. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
21. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
22. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996;125:634-9.
23. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, Deleo VA, Harber LC. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1997;67:277-86.
24. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321-3.
25. Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbatta N, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998;27:181-4.
26. Hift RJ, Kirsch RE. Porphyria cutanea tarda as a manifestation of alcohol-induced liver disease. In: Hall P, editor. Alcoholic liver disease, 2nd ed. London: Edward Arnold; 1995:219-31.
27. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999;29:1596-601.
28. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepatol 2001;8:1-18.
29. Bissell DM. Sex and hepatic fibrosis. Hepatology 1999;29:988-99.
30. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999;29:719-27.
31. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997;349:825-32.
32. Mochida S, Ohnishi K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 1996;20:371A-7A.
33. Olynyk J, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995;108:1104-9.
34. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994 20:410-5.
35. Tannapfel A, Stölzel U, Köstler E, Melz S, Richter M, Keim V, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchow Arch 2001;439:1-5.
36. Jouët P, Roudot-Thoraval F, Dhumeaux D, Métreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Francais pour l'etude du traitement des hépatites chroniques NANB/C. Gastroenterology 1994;106:686-90.
37. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998;29:214-23.
38. Lamoril J, Andant C, Bogard C, Puy H, Gouya L, Pawlotsky JM, et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998;27:848-52.